Pacira Biosciences Inc (PCRX) Stock AnalysisPCRXPacira Biosciences Inc

Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pacira Biosciences Inc is currently a hold. The stock price is at $36.31, just below the acquisition price of $36.50, which limits upside potential. The RSI is at 93.272, indicating the stock is overbought, suggesting caution. While the acquisition by Viatris represents a 45% premium over the previous closing price, the significant insider selling (636.27% increase) raises concerns about future performance post-acquisition. The main risk is the stock's current valuation with a P/E ratio of 99.1, which is quite high, indicating potential overvaluation.

16 analysts cover PCRX: 10 rate it Buy, 5 Hold and 1 Sell. The average price target is 30.33.